This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, announced today that the Company will file its Form 10-K for 2012 with the U.S. Securities and Exchange Commission (SEC) after market close on Thursday, March 28, will report 2012 fourth quarter and full year financial results via a news release to be issued premarket Monday, April 1 and will hold an investment community conference call to discuss the financial results and answer questions at 11:00 a.m. Eastern time April 1. The timing of these various activities reflects SEC filing deadlines and the closure of the U.S. stock markets on Friday, March 29.
To access the conference call, please dial (888) 563-6275 from within the U.S. or (706) 634-7417 from outside the U.S. All listeners should provide passcode 24248661. Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Company’s website at
Following the conclusion of the conference call, a replay will be available through April 6, 2013 and can be accessed by dialing (855) 859-2056 from within the U.S. or (404) 537-3406 from outside the U.S. All listeners should provide passcode 24248661. The webcast will be available for 30 days.
About Derma Sciences, Inc.
Derma Sciences is a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care products, advanced wound care dressings to address chronic wounds, including diabetic ulcers and traditional dressings. The Company has begun Phase 3 clinical trials in diabetic foot ulcer healing with DSC127, based on excellent Phase 2 data. Its MEDIHONEY® product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of indications, and was the focus of a positive large-scale, randomized controlled trial involving 108 subjects with leg ulcers. TCC-EZ® is its gold-standard total contact casting system for diabetic foot ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB® for better management of wound exudate, and BIOGUARD® for infection prevention.